title: Evaluation of periodic limb movements in a putative animal model of restless leg syndrome.
abstract: Restless leg syndrome (RLS) is a major healthcare burden with increasing prevalence. It has been demonstrated that periodic limb movements (PLM) can occur as an isolated phenomenon, but they are often associated with this syndrome and are the only symptom of this disorder that can be measured electrophysiologically. The aim of this study was to examine the sleep-wake behavior and the presence of limb movement in a rat model of RLS induced by lesioning the A11 dopaminergic nuclei with the neurotoxin 6-hydroxydopamine (6-OHDA). Rats were implanted with electrodes for electrocorticography and electromyography. Sleep recordings were monitored during light/dark periods lasting 12 hours each and were evaluated on days 7, 15, and 28 after injection of the drug or phosphate-buffered saline (PBS). A control group that did not receive any injection was also included. Wakefulness percentages were generated for 4-hour segments of the dark period, yielding the following 3 bins: 7 PM to 11 PM, 11 PM to 3 AM, and 3 PM to 7 PM. Additionally, slow wave sleep, paradoxical sleep, wakefulness, and limb movements were evaluated over the entire 12 hours of the light/dark cycle. All A11-lesioned rats exhibited an increased percentage of wakefulness during the last block of the dark period, as would be expected for an animal model of this syndrome. In addition, at all time points after lesioning, these animals presented increased frequencies of limb movement during both the light and the dark periods. These alterations were reversed by the acute administration of the dopaminergic agonist pramipexole. This animal model strengthens the notion that 6-OHDA-induced A11 lesions can be a valid animal model for RLS and PLM.
authors.affiliation: Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
authors.forename: Cleide
authors.initials: C
authors.lastname: Lopes
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Esteves
authors.forename: Roberto
authors.initials: R
authors.lastname: Frussa-Filho
authors.forename: Sergio
authors.initials: S
authors.lastname: Tufik
authors.forename: Marco Tulio
authors.initials: MT
authors.lastname: de Mello
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D052160:Benzothiazoles / Q000627:therapeutic use; D004195:Disease Models, Animal; D004569:Electroencephalography; D004576:Electromyography; D005121:Extremities / Q000503:physiopathology; D008297:Male; D009068:Movement / Q000502:physiology; D020189:Nocturnal Myoclonus Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D016627:Oxidopamine / Q000633:toxicity; D000077487:Pramipexole; D051381:Rats; D017208:Rats, Wistar; D012148:Restless Legs Syndrome / Q000139:chemically induced / Q000150:complications*; D013565:Sympatholytics / Q000633:toxicity; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D017557:Ventral Tegmental Area / Q000378:metabolism / Q000473:pathology
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D013565:Sympatholytics; D000077487:Pramipexole; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase